Company / Cash & Equivalents
IQVIA Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.0B
FY2025
5-year range
$1.2B / $2.0B
FY2021-FY2025
Trend
+16.3%
vs FY2024
Sector context
#19 of 148
Health Care
What the data says
IQVIA's cash & equivalents of $2.0B is higher than 87% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 3 consecutive years, from $1.2B in FY2022 to $2.0B in FY2025.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +1.8%. Top quartile in the Health Care sector.
Improved from $1.4B to $2.0B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- +1.8%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 148This company $2.0B Sector average $1.2B
▼
+68.3% above sector average
Key checks
Key Insights
- IQVIA's cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +1.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 16.3% year-over-year.
- Ranks #19 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 20.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +16.3% |
| FY2024 | $1.7B | +23.7% |
| FY2023 | $1.4B | +13.2% |
| FY2022 | $1.2B | -11.0% |
| FY2021 | $1.4B | -24.7% |
| FY2020 | $1.8B | +116.7% |
| FY2019 | $837.0M | -12.7% |
| FY2018 | $959.0M | +0.0% |
| FY2017 | $959.0M | -19.9% |
| FY2016 | $1.2B | +22.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026